Therapeutic potential of mesenchymal stem cells from human iPSC‐derived teratomas for osteochondral defect regeneration

Abstract

AbstractHuman induced pluripotent stem cells (iPSCs) hold great promise for personalized medicine, as they can be differentiated into specific cell types, especially mesenchymal stem cells (MSCs). Therefore, our study sought to assess the feasibility of deriving MSCs from teratomas generated from human iPSCs. Teratomas serve as a model to mimic multilineage human development, thus enriching specific somatic progenitors and stem cells. Here, we discovered a small, condensed mass of MSCs within iPSC‐generated teratomas. Afterward, we successfully isolated MSCs from this condensed mass, which was a byproduct of teratoma development. To evaluate the characteristics and cell behaviors of iPSC‐derived MSCs (iPSC‐MSCs), we conducted comprehensive assessments using qPCR, immunophenotype analysis, and cell proliferation‐related assays. Remarkably, iPSC‐MSCs exhibited an immunophenotype resembling that of conventional MSCs, and they displayed robust proliferative capabilities, similar to those of higher pluripotent stem cell‐derived MSCs. Furthermore, iPSC‐MSCs demonstrated the ability to differentiate into multiple lineages in vitro. Finally, we evaluated the therapeutic potential of iPSC‐MSCs using an osteochondral defect model. Our findings demonstrated that teratomas are a promising source for the isolation of condensed MSCs. More importantly, our results suggest that iPSC‐MSCs derived from teratomas possess the capacity for tissue regeneration, highlighting their promise for future therapeutic applications.